Literature DB >> 7644521

Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts.

X Lu1, W Xie, D Reed, W S Bradshaw, D L Simmons.   

Abstract

Programmed cell death (apoptosis) is an intrinsic part of organismal development and aging. Here we report that many nonsteroidal antiinflammatory drugs (NSAIDs) cause apoptosis when applied to v-src-transformed chicken embryo fibroblasts (CEFs). Cell death was characterized by morphological changes, the induction of tissue transglutaminase, and autodigestion of DNA. Dexamethasone, a repressor of cyclooxygenase (COX) 2, neither induced apoptosis nor altered the NSAID effect. Prostaglandin E2, the primary eicosanoid made by CEFs, also failed to inhibit apoptosis. Expression of the protooncogene bcl-2 is very low in CEFs and is not altered by NSAID treatment. In contrast, p20, a protein that may protect against apoptosis when fibroblasts enter G0 phase, was strongly repressed. The NSAID concentrations used here transiently inhibit COXs. Nevertheless, COX-1 and COX-2 mRNAs and COX-2 protein were induced. In some cell types, then, chronic NSAID treatment may lead to increased, rather than decreased, COX activity and, thus, exacerbate prostaglandin-mediated inflammatory effects. The COX-2 transcript is a partially spliced and nonfunctional form previously described. Thus, these findings suggest that COXs and their products play key roles in preventing apoptosis in CEFs and perhaps other cell types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644521      PMCID: PMC41266          DOI: 10.1073/pnas.92.17.7961

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Rapid transformation of cells by Rous sarcoma virus.

Authors:  H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1969-06       Impact factor: 11.205

2.  Towards a better aspirin.

Authors:  J Vane
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

3.  Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes.

Authors:  G E Evett; W Xie; J G Chipman; D L Robertson; D L Simmons
Journal:  Arch Biochem Biophys       Date:  1993-10       Impact factor: 4.013

4.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

5.  Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products.

Authors:  M P Peppelenbosch; L G Tertoolen; W J Hage; S W de Laat
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

Review 6.  Implantation and decidualization in rodents.

Authors:  P A Abrahamsohn; T M Zorn
Journal:  J Exp Zool       Date:  1993-09-01

7.  Bcl-2 blocks p53-dependent apoptosis.

Authors:  S K Chiou; L Rao; E White
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

8.  Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells.

Authors:  C C Pilbeam; H Kawaguchi; Y Hakeda; O Voznesensky; C B Alander; L G Raisz
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

9.  Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV.

Authors:  A Mastino; S Grelli; M Piacentini; S Oliverio; C Favalli; C F Perno; E Garci
Journal:  Cell Immunol       Date:  1993-11       Impact factor: 4.868

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  38 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.

Authors:  O Gallo; A Franchi; L Magnelli; I Sardi; A Vannacci; V Boddi; V Chiarugi; E Masini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

4.  Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein.

Authors:  B A Ballif; N V Mincek; J T Barratt; M L Wilson; D L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

5.  Newly identified stress-responsive protein kinases, Krs-1 and Krs-2.

Authors:  L K Taylor; H C Wang; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

6.  Pleiotropic action of AP-1 in v-Src-transformed cells.

Authors:  Lizhen Wang; Natalie A Rodrigues; Ying Wu; Bart M Maslikowski; Nishi Singh; Samantha Lacroix; Pierre-André Bédard
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

7.  Regulatory role of prostaglandin E2 in induction of cyclo-oxygenase-2 by a thromboxane A2 analogue (U46619) and basic fibroblast growth factor in porcine aortic smooth-muscle cells.

Authors:  S Karim; E Berrou; S Lévy-Toledano; M Bryckaert; J MacLouf
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

8.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.

Authors:  C S Williams; H Sheng; J A Brockman; R Armandla; J Shao; M K Washington; A G Elkahloun; R N DuBois
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

9.  Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.

Authors:  Bruce I Gaynes; Anne Onyekwuluje
Journal:  Clin Ophthalmol       Date:  2008-06

10.  Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Authors:  Devin G Roller; Mark Axelrod; Brian J Capaldo; Karin Jensen; Aaron Mackey; Michael J Weber; Daniel Gioeli
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.